Literature DB >> 2174658

Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events.

E Rozengurt1.   

Abstract

Quiescent cultures of Swiss 3T3 cells can be stimulated to recommence DNA synthesis by polypeptide growth factors, neuropeptides, and various pharmacologic agents that act via multiple signal transduction pathways. Neuropeptides of the bombesin family provide potent mitogens to elucidate these pathways. These peptides bind to specific receptors that have been characterized by radioligand binding and sensitivity to antagonists and identified as glycoproteins with a Mr of 75,000-85,000 by chemical cross-linking. After binding, bombesin elicits a cascade of early molecular events including stimulation of phosphorylation of the acidic Mr 80,000 cellular protein, which is a major substrate of protein kinase C; Ca2+ mobilization mediated by Ins(1,4,5)P3, Na+ and K+ fluxes, transmodulation of EGF receptor, enhancement of cAMP accumulation, and expression of the proto-oncogenes c-fos and c-myc. Studies using membrane preparations and permeabilized 3T3 cells indicate that G proteins play a role in the transduction of the mitogenic signal triggered by the binding of bombesin to its receptor. A pertussis toxin-insensitive G protein couples the bombesin receptor to the generation of a signal that activates protein kinase C, whereas a pertussis toxin-sensitive G protein mediates cross-talk between transmembrane signaling pathways. Bombesin-mediated mitogenesis can be blocked by different antagonists and by interrupting the signal-transduction process at various postreceptor levels. Thus, prolonged treatment with vasopressin causes heterologous desensitization to the mitogenic action of bombesin. This mitogenic block is mediated by uncoupling the receptor from its signaling system. Loss of responsiveness to bombesin-stimulated DNA synthesis is also induced by down-regulation of protein kinase C.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174658     DOI: 10.1164/ajrccm/142.6_Pt_2.S11

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  Gastrin-releasing peptide is a growth factor for human neuroblastomas.

Authors:  Sunghoon Kim; Wanqin Hu; David R Kelly; Mark R Hellmich; B Mark Evers; Dai H Chung
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

2.  Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence.

Authors:  C Liebow; D H Crean; A V Schally; T S Mang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

3.  Specific antibodies elicited by a novel DNA vaccine targeting gastrin-releasing peptide inhibit murine melanoma growth in vivo.

Authors:  Jing Fang; Yong Lu; Kedong Ouyang; Guojun Wu; Huiyong Zhang; Yanhua Liu; Yingying Chen; Ming Lin; Huaqian Wang; Liang Jin; Rongyue Cao; Rouel S Roque; Li Zong; Jingjing Liu; Taiming Li
Journal:  Clin Vaccine Immunol       Date:  2009-05-20

4.  Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors.

Authors:  Manu Jaggi; Sudhanand Prasad; Anu T Singh; R Praveen; Sarjana Dutt; Archana Mathur; Rajan Sharma; Neena Gupta; Rinku Ahuja; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2008-01-24       Impact factor: 3.850

5.  Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.

Authors:  Y Qin; G Halmos; R Z Cai; B Szoke; T Ertl; A V Schally
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Bombesin antagonist prevents CO2 laser-induced promotion of oral cancer.

Authors:  M F Kozacko; T S Mang; A V Schally; R L Priore; C Liebow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

Review 7.  Targeting prostate cancer with radiolabelled bombesins.

Authors:  Theodosia Maina; Berthold Nock; Stephen Mather
Journal:  Cancer Imaging       Date:  2006-11-08       Impact factor: 3.909

8.  In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.

Authors:  V G Brunton; P Workman
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.